Search company, investor...

Talon Therapeutics

talontx.com

Founded Year

2002

Stage

Acq - P2P | Acquired

Total Raised

$8M

Valuation

$0000 

About Talon Therapeutics

Talon Therapeutics (Nasdaq:TLON) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates and expanding its pipeline by being the alliance partner of choice. The company was formerly known as Hana Biosciences and changed it's name to Talon Therapeutics in December 2010. It was founded in 2002 and is based in South San Francisco, California.

Headquarters Location

400 Oyster Point Boulevard Suite 200

South San Francisco, California, 94080,

United States

650-588-6404

Missing: Talon Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Talon Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Talon Therapeutics Patents

Talon Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/15/2013

3/21/2017

Cosmetics, Dosage forms, Skin care, Drug delivery devices, Fluid dynamics

Grant

Application Date

10/15/2013

Grant Date

3/21/2017

Title

Related Topics

Cosmetics, Dosage forms, Skin care, Drug delivery devices, Fluid dynamics

Status

Grant

Latest Talon Therapeutics News

Spectrum Pharmaceuticals Acquires Talon Therapeutics

Aug 24, 2022

July 17, 2013 07:00 ET San Mateo, California, UNITED STATES SOUTH SAN FRANCISCO, Calif., July 17, 2013 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCQB:TLON) today announced that a subsidiary of Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI) entered into an agreement to purchase approximately 89% of the outstanding shares of Talon (the "Company") directly from the Company's principal stockholders. Spectrum also entered into an agreement with the Company under which the subsidiary of Spectrum will purchase additional shares from the Company that, together with the shares acquired from the Company's principal stockholders, will represent in excess of 90% of the outstanding shares of Talon, and under which Spectrum will acquire the remaining outstanding shares of Company common stock through a "short-form" merger of the subsidiary of Spectrum into the Company. The Company and Spectrum expect that the share purchase and the merger will be completed within one business day. Spectrum will pay aggregate upfront cash consideration in connection with the closing of the acquisition of approximately $11.3 million to Company stockholders, and Company stockholders will also receive contingent value rights (CVRs) to receive an aggregate of up to $195 million in future cash payments from Spectrum upon the achievement of certain one-time sales-based milestones for Marqibo® and an approval-based milestone for Menadione Topical Lotion. There can be no assurance as to the actual value, if any, of a CVR, which will depend on numerous factors. The CVRs will not be publicly traded. The per share purchase price for each outstanding share of Company common stock payable at closing to the Company's stockholders, including the Company's principal stockholders, is approximately $0.056 in cash plus one CVR right. Spectrum will also issue 3 million shares of its common stock in exchange for all of the outstanding indebtedness under the Company's credit facility and will pay certain related accrued interest. The transaction was reviewed by a special independent committee of the Board of Directors of Talon, which recommended the transactions for approval by the full Board. Houlihan Lokey acted as financial advisor to the special committee in connection with the proposed transaction. The Board of Directors of Talon, based on a review of factors that it considered relevant, including the unanimous recommendation of the special independent committee, approved the transaction. The Company expects that its shares will cease trading on the OTCQB market effective prior to the open of market on July 18, 2013. Corporate Stock Transfer, Inc., acting as the paying agent for the merger, will mail to the remaining former Company stockholders materials necessary to exchange their Company shares for payment. Additionally, the paying agent will distribute an appraisal rights notice containing additional detail regarding the transaction and the consideration received by common stockholders within 10 days following the closing of the merger. About Talon Therapeutics Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees. In addition to Marqibo® (vinCRIStine sulfate LIPOSOME injection) which received accelerated approval from the US FDA for the treatment of Philadelphia chromosome negative adult acute lymphoblastic leukemia (ALL) patients in second or greater relapse or whose disease has progressed following two or more prior lines of anti-leukemia therapy, Talon has additional pipeline opportunities some of which like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. About Spectrum Pharmaceuticals, Inc. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market three oncology drugs ─ FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com . Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Talon Therapeutics and Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements regarding the timing and completion of the share acquisitions and the merger, the success and strategic fit of Talon within Spectrum, the potential value of the consideration to be received by Talon's stockholders in connection with the acquisition by Spectrum, including, without limitation, the achievement of certain milestones and Spectrum's ability to commercialize Marqibo. Risks that could cause actual results to differ include the possibility that the drug candidates may not prove safe or effective, the possibility that existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that the drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in Talon's and Spectrum's reports filed with the Securities and Exchange Commission. Neither Talon nor Spectrum plans to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

Talon Therapeutics Frequently Asked Questions (FAQ)

  • When was Talon Therapeutics founded?

    Talon Therapeutics was founded in 2002.

  • Where is Talon Therapeutics's headquarters?

    Talon Therapeutics's headquarters is located at 400 Oyster Point Boulevard, South San Francisco.

  • What is Talon Therapeutics's latest funding round?

    Talon Therapeutics's latest funding round is Acq - P2P.

  • How much did Talon Therapeutics raise?

    Talon Therapeutics raised a total of $8M.

  • Who are the investors of Talon Therapeutics?

    Investors of Talon Therapeutics include Spectrum Pharmaceuticals, Coqui Capital Partners, Balyasny Asset Management, Mosaix Ventures, Pogue Capital Management and 23 more.

  • Who are Talon Therapeutics's competitors?

    Competitors of Talon Therapeutics include LungLife AI, DNAtriX, NGM Biopharmaceuticals, Catalyst Biosciences, Telormedix and 12 more.

Compare Talon Therapeutics to Competitors

C
Cell Therapeutics

CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In the company's pursuit of making cancer more treatable, they are developing a diversified portfolio of oncology products focused on identifying and developing new, less toxic, and more effective ways to treat cancer.

LungLife AI Logo
LungLife AI

LungLife AI is focused on the development of the LiquidBiopsy platform, a high-performance rare cell isolation technology for biomedical research and cancer diagnostics. LiquidBiopsy is a key enabling technology to realize the promise of personalized medicine, including the early detection of disease, real-time monitoring of patients, and the selection of individual therapeutic solutions.

DNAtriX Logo
DNAtriX

DNAtrix is developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells.

Q
Qyntessa Biologics

Qyntessa Biologics aims to provide clinical manufacturing, (cGMP biologics manufacturing), process development, cell banking, cell line development, testing and fill/finish for researchers and biopharmaceutical companies who do not have the facilities and competencies for clinical manufacturing.

Bio-Link Logo
Bio-Link

Bio-Link is a National Advanced Technological Education (ATE) Center for Biotechnology that originated in late 1998 with a grant from the National Science Foundation. The ATE program was created to improve and expand educational programs that prepare skilled technicians to work in the high-tech fields that drive the U.S. economy. Bio-Link enhances and expands biotechnology education programs by providing professional development for instructors, by improving curriculum, by making use of technologies and by creating a system that promotes the sharing of information. The Bio-Link National Center is at City College of San Francisco with office space at the University of California San Francisco. Regional Bio-Link Centers across the country are located in Seattle, WA; San Diego, CA; San Francisco, CA; Austin, TX; Madison, WI; Graham, NC; and Portsmouth, NH. The regional centers develop relations with local industry and educational institutions including community colleges, baccalaureate institutions, and high schools. In addition, each regional center spearheads a different element of the program. Bio-Link is supporting a cadre of well-trained instructors and is increasing the number and quality of biotechnology programs for students. Bio-Link aiming to bring a range of underrepresented students to biotechnology who have the knowledge and skills essential to the field as well as the ability to continue with more advanced education in math, science and engineering. At a press conference, on October 15th, 1998, at City College of San Francisco (CCSF), Chancellor Philip R. Day, Jr. stated, "Bio-Link represents a opportunity for community colleges to take a lead in technical training and retraining for the skilled biotechnology workforce of the twenty-first century."nnDr. Elaine Johnson, Director of the National Center and faculty member of CCSF remarked, "In making this award, NSF recognizes both the importance of creating a high performance technical workforce for a competitive global economy and the critical role community and technical colleges play in the education of technicians."

N
NanoBioNexus

Founded in 2004, NanoBioNexus has grown to be a nanobiotechnology industry organization that showcases the latest nanotechnology research with a special interest in life sciences. Headquartered in San Diego, California and with offices in Tucson AZ, San Jose California and Vancouver WA, NanoBioNexus and its affiliate University Chapters aims to provide regular forums that present relevant nanotechnologies and discusses the impact and opportunities for industry professionals, academics, commercial companies and investors. Issues and challenges vital to this emerging field are also examined with scientific experts and industry pundits.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.